What Will Happen to IMMUPHARMA PLC ORD UNITED KINGDO (OTCMKTS:IMMPF) Next? The Stock Has Decline in Shorts

February 14, 2018 - By Kurt Siggers

The stock of IMMUPHARMA PLC ORD UNITED KINGDO (OTCMKTS:IMMPF) registered a decrease of 64.52% in short interest. IMMPF’s total short interest was 1,100 shares in February as published by FINRA. Its down 64.52% from 3,100 shares, reported previously. With 100 shares average volume, it will take short sellers 11 days to cover their IMMPF’s short positions.

It closed at $1.88 lastly. It is down 0.00% since February 14, 2017 and is . It has underperformed by 16.70% the S&P500.

ImmuPharma plc, a pharmaceutical company, develops drug candidates based on peptide therapeutics to treat serious medical conditions. The company has market cap of $233.38 million. The companyÂ’s lead product candidate is the Lupuzor, which is in Phase III clinical trials for the treatment of lupus, an autoimmune chronic inflammatory disease. It currently has negative earnings. The Company’s other product candidates include IPP-204106, an anti-cancer nucleolin antagonis peptide program that has completed Phase I/IIa clinical trials to treat cancer; IPP-102199, which is in pre-clinical development stage to treat severe pain; IPP-201007 that is in early development stage for the treatment of inflammatory and allergic conditions, such as asthma and other respiratory disorders, rheumatoid arthritis, septic shock, and acute pancreatitis; and IPP-203101, a peptide antibiotic, which is in pre-clinical development stage for the treatment of lethal infections, including methicillin-resistant staphylococcus aureus and other hospital acquired infections.

Another recent and important ImmuPharma plc (OTCMKTS:IMMPF) news was published by Fiercebiotech.com which published an article titled: “ImmuPharma rounds up £8.3M for PhIII trial of fast-tracked lupus drug” on February 10, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: